Sign Up to like & get
recommendations!
0
Published in 2025 at "American Journal of Clinical Pathology"
DOI: 10.1093/ajcp/aqaf121.418
Abstract: Immune checkpoint inhibitors (ICI) enhance anti-tumor immunity but can cause ICI-related immune hemolytic anemia (Ir-IHA). Distinguishing direct antiglobulin test (DAT)- negative Ir-IHA from non-immune hemolytic anemia (HA) is challenging, and limited data exist on immunohematology…
read more here.
Keywords:
iha;
dat;
hemolytic anemia;
checkpoint ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Transfusion"
DOI: 10.1111/trf.16360
Abstract: Oxaliplatin, a third‐generation platinum derivative is commonly used in combination treatment of metastatic colorectal cancer. Since 2008, it is the second most common cause of drug‐induced immune hemolytic anemia (DIIHA) investigated in our laboratory.
read more here.
Keywords:
hemolytic anemia;
immune hemolytic;
induced immune;
drug induced ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0274464
Abstract: Background Immune hemolytic anemia commonly affects human immune deficiency infected individuals. Among anemic HIV patients in Africa, the burden of IHA due to autoantibody was ranged from 2.34 to 3.06 due to drug was 43.4%.…
read more here.
Keywords:
infected adults;
hemolytic anemia;
immune hemolytic;
virus infected ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1478545
Abstract: Piperacillin is a beta-lactamase inhibitor frequently used in the treatment of urinary tract infections. It is a broad-spectrum antibiotic with strong antibacterial action against Pseudomonas aeruginosa and Enterobacter, especially extended-spectrum beta-lactamase-producing Enterobacteria and Enterococcus. Side…
read more here.
Keywords:
caused piperacillin;
report;
anemia;
hemolytic anemia ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1586426
Abstract: Background Immune-hemolytic anemia (IHA) is a rare immune-related adverse event (irAE) in cancer patients treated with immune-checkpoint inhibitors (ICIs). Although several cases of ICI-associated IHA have been reported, few attempts have been made to collate…
read more here.
Keywords:
scoping review;
ici associated;
immune hemolytic;
associated iha ... See more keywords